320MO Tibremciclib (BPI-16350) plus fulvestrant in patients with HR+/HER2- advanced breast cancer after progressing on endocrine therapy: A randomized, multicenter, double-blind, phase III study

作者：X. Hu, Z. Tao, Shuo Wang, Jianzhi Zhang, Qiaoli Zheng, Yang Wang, L. Cai, Haojun Xu, Xiaohong Xu, X. Kong, Sentai Ding, Changfu Hao, H. Wang, Hong Zong, Xiance Jin, Xian Wang, Y. Li, Xiao-Yi Yang, Lu Ding, Pei Li · 发表于：Annals of Oncology · 年份：2024 · DOI：10.1016/j.annonc.2024.08.259 · 被引用次数：4 · 研究领域：Advanced Breast Cancer Therapies、Cancer Treatment and Pharmacology、HER2/EGFR in Cancer Research